MedPath

A comparative study of two different local anaesthetic drugs given epidurally for relieving postoperative pain after major abdominal cancer surgery.

Phase 3
Completed
Conditions
Patients Undergoing Major Abdominal Oncosurgery
Registration Number
CTRI/2016/06/007039
Lead Sponsor
Rajiv Gandhi Cancer Institute and Research Centre
Brief Summary

This is a prospective, randomized, double blind ,parallel group, active controlled, single centric interventional trial comparing the analgesic efficacy of epidural ropivacaine with fentanyl and bupivacaine with fentanyl after major abdominal oncosurgery at fixed time points in 60 patients of either sex at Rajiv Gandhi Cancer Institute and Research Centre.VAS Sore for postoperative pain relief is the primary outcome measure and Bromage Score for motor blockade is the secondary outcome measure at various time points of 10 minutes, 1hour, 6 hours, 12 hours, 18 hours and 24 hours postoperatively

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
60
Inclusion Criteria

Weight between 45-75 Kg ASA Physical Status I, II and III Elective major oncosurgery via a vertical, midline infraumbilical incision.

Exclusion Criteria

Patient refusal for Regional Anaesthesia Contraindications for Regional Anaesthesia(coagulopathy,regional infection) History of allergic reaction to Bupivacaine, Ropivacaine or Fentanyl Spinal deformity.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
VAS score for postoperative pain10mins,1hour,6hour,12hour,18 hour and 24 hour
Secondary Outcome Measures
NameTimeMethod
Bromage Score for motor blockade10 mins,1hour,6 hours,12 hours,18 hours and 24 hours

Trial Locations

Locations (1)

Rajiv Gandhi Cancer Institute and Research Centre

🇮🇳

West, DELHI, India

Rajiv Gandhi Cancer Institute and Research Centre
🇮🇳West, DELHI, India
Dr Anita Kulkarni
Principal investigator
9891064785
anitackulkarni@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.